Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Status:
Completed
Trial end date:
2020-07-27
Target enrollment:
Participant gender:
Summary
Two recent studies have suggested that in patients with Covid19, treatment with
hydroxychloroquine may shorten the duration of symptoms and improve viral clearance, an
effect that appears most pronounced when combined with azithromycin. Hydroxychloroquine
treatment may inhibit viral nucleic acid-mediated activation of various innate immune
pathways, as well as blockade of lysosomal functions in cell types relevant for viral entry
and antigen presentation.
The purpose of the study was to determine if oral hydroxychloroquine monotherapy, or in
combination with azithromycin results in clinical benefit in patients hospitalized with
COVID19 pneumonia.